GH Research
GHRS
34 hedge funds and large institutions have $352M invested in GH Research in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 0 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
48% more capital invested
Capital invested by funds: $237M → $352M (+$114M)
17% more funds holding
Funds holding: 29 → 34 (+5)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
0.11% less ownership
Funds ownership: 57.08% → 56.97% (-0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$9.94M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
+$1.56M |
| 3 |
Renaissance Technologies
New York
|
+$151K |
| 4 |
CC
Corton Capital
Carrying Place,
Ontario, Canada
|
+$124K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$109K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$9.46M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.53M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$1.48M |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$185K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$41.2K |
GHRS Hedge Fund Activity: Q2 2023 in Review
34 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in GH Research (GHRS) for Q2 2023, worth a combined $352M — up 48% from $237M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new GHRS positions and 0 closed out — a net gain of 5 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $9.94M. The largest seller was OrbiMed, cutting an estimated $9.46M.
- 34 institutional investors held GH Research (GHRS) as of Q2 2023, up from 29 in Q1 2023.
- Funds reported $352M of GH Research stock for Q2 2023, up 48% quarter-over-quarter.
- 5 funds opened new GH Research positions in Q2 2023 and 0 closed out, a net change of +5 holders.
- The largest GH Research buyer in Q2 2023 was Lynx1 Capital Management, an estimated $9.94M added.
- The largest GH Research seller in Q2 2023 was OrbiMed, an estimated $9.46M sold.
Based on aggregated 13F filings for Q2 2023.